Modality
siRNA
MOA
TROP-2 ADC
Target
SMN2
Pathway
Apoptosis
PAHMSHS
Development Pipeline
Preclinical
Feb 2025
→ Aug 2030
PreclinicalCurrent
NCT03595795
2,549 pts·HS
2025-02→2030-08·Recruiting
2,549 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-174.4y awayInterim· HS
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2030-08-17 · 4.4y away
HS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03595795 | Preclinical | HS | Recruiting | 2549 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |